Laurion Capital Management LP Gilead Sciences, Inc. Call Options Transaction History

Laurion Capital Management LP

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2021 Nov 15, 2021	BUY	$67.69 - $73.03 $4.74 Million - $5.11 Million	70,000 New	70,000 $4.89 Million
Q1 2020 May 14, 2020	SELL	$62.63 - $80.22 $11.3 Million - $14.4 Million	-180,000 Closed	0 $0
Q4 2019 Feb 13, 2020	SELL	$61.62 - $67.78 $22 Million - $24.2 Million	-356,800 Reduced 66.47%	180,000 $11.7 Million
Q3 2019 Nov 13, 2019	BUY	$62.51 - $69.0 $6.8 Million - $7.51 Million	108,800 Added 25.42%	536,800 $34 Million
Q2 2019 Aug 13, 2019	BUY	$61.87 - $69.38 $26.5 Million - $29.7 Million	428,000 New	428,000 $28.9 Million
Q1 2019 May 08, 2019	SELL	$62.53 - $70.05 $17.6 Million - $19.7 Million	-280,800 Closed	0 $0
Q4 2018 Feb 14, 2019	SELL	$60.54 - $79.0 $2.13 Million - $2.78 Million	-35,200 Reduced 11.14%	280,800 $17.6 Million
Q3 2018 Nov 13, 2018	BUY	$71.28 - $78.92 $3.88 Million - $4.3 Million	54,500 Added 20.84%	316,000 $24.4 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $12.9 Million - $15.8 Million	-177,500 Reduced 40.43%	261,500 $19.7 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $31.7 Million - $37.5 Million	439,000	439,000 $35.6 Million

1,895

1.02B

12M

9.02M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $111B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.